In the Claims

1-6. (Cancelled)

7. (Currently Amended) A transdermal therapeutic system comprising at least one active agent which comprises:

a) a backing layer that is remote from the skin and impermeable to the active agent,

b) at least one active agent depot,

c) a matrix which contains the active agent depot and controls the delivery of the active agent, and

d) a pressure sensitive fixing device for the therapeutic system on the skin, wherein the active agent depot, the matrix or both comprise a support material, wherein the support material consists of paper, and the active agent is selected from the group consisting of lidocaine, diphenylhydramine hydrochloride, salbutamol, 5-fluorouracil, a sexual hormone, a gestagen and fentanyl.

8. (Cancelled)

9. (Previously Presented) The transdermal therapeutic system according to claim 8, wherein the sexual hormone is selected from the group consisting of estradiol, norethindronacetate and levonorgestrel.

10. (Previously Presented) The transdermal therapeutic system according to claim 7, wherein the paper has a weight of from 9 to 60 g/m^2.

11. (Previously Presented) The transdermal therapeutic system according to claim 10, wherein the paper has a weight of from 15 to 40 g/m^2.

12. (Previously Presented) The transdermal therapeutic system according to claim 10, wherein the paper has a weight of from 20 to 35 g/m^2.

13. (Previously Presented) A process for the manufacture of a transdermal therapeutic system comprising at least one active agent and having a range of variation of the amount of active agent applied being lower than 2%, which comprises applying the active agent by means of a tampon to a support material consisting of paper.

14. (Previously Presented) The process according to claim 13, wherein the range of variation is lower then 1.2%.

15. (Previously Presented) The transdermal system according to claim 7, wherein only the active agent depot comprises a support material and the support material consists of paper.